Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03031262
PHASE1/PHASE2

Efficacy and Safety of Chidamide in CBF Leukemia

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

Summary

In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.

Key Details

Gender

All

Age Range

14 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2017-02-08

Completion Date

2027-12-30

Last Updated

2025-05-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Cytarabine

Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

DRUG

Chidamide

Chidamide at a dose of 20mg/d twice a week for 3 months.

Locations (1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China